April 2, 2013
/PRNewswire/ -- SonaCare Medical, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, successfully launched two new products at the recent European Association of Urology (EAU) Congress in
Generating significant interest in its platform technology to provide HIFU surgical ablation for a wide range of urological indications, SonaCare Medical showcased the updated
500 with a redesigned software interface featuring new treatment planning and enhanced simulation capabilities along with the new FDA 510(k) cleared laparoscopic soft tissue ablation device,
HIFU Surgical Ablation System. SonaCare Medical experienced record attendance at its EAU booth where physicians were able to plan simulated treatments using
new high frequency simulator showcasing the technology's ability to treat a cubic centimeter of tissue per minute with +/- 1mm precision.
ability to be introduced via a standard laparoscopic port, in conjunction with its easy-to-use intuitive single screen control interface, drew significant attention from laparoscopic and robotic users alike. The number of physicians without prior HIFU experience who came by to examine the system also was impressive," says
, Vice President of International Operations for SonaCare Medical. "Featured alongside our flagship product, the new
Sonablate ® 500,
was well received and will continue to build the installed base for the company. With FDA clearance in the U.S. for laparoscopic or intraoperative soft tissue ablation, we have immediate ability to take orders and deliver
Hosting dozens of European key opinion leaders (KOLs) from multiple urology disciplines at its international HIFU users group meetings, the company reviewed its HIFU platform technology vision to develop HIFU surgical ablation systems for a wide range of urological indications.